Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nextleaf Solutions Ltd C.OILS

Alternate Symbol(s):  OILFF

Nextleaf Solutions Ltd. is a cannabis processor with a portfolio of federally regulated emerging consumer brands, market validated cannabis derivative products, and high-potency bulk ingredients. The Company’s multi-patented, highly automated, closed loop extraction, and distillation technology sets the global standard for processing cannabis at scale. The Company manufactures over 80 different products, across four categories for white label clients and house brands. It manufactures and distributes cannabis vapes and oils under multiple brands including its brand, Glacial Gold, and the High Plains brand. The Company sells its branded cannabinoid vapes, oils, and soft gels to the British Columbia Liquor Distribution Branch (BCLDB), Ontario Cannabis Store (OCS), Nova Scotia Liquor Commission (NSLC), Manitoba Liquor & Lotteries (MBLL) National Cannabis Distribution in Saskatchewan, and across Canada through multiple medical platforms, select pharmacies, and a distribution agreement.


CSE:OILS - Post by User

Comment by lscfaon Feb 09, 2021 4:53pm
136 Views
Post# 32516862

RE:RE:RE:GW Pharma was just bought for $7B

RE:RE:RE:GW Pharma was just bought for $7B

Canopy will lose.   GW's assigned patent was first.    The problem with patents is you disclose to the world your formula and others can just tweek it to avoid infringement. That's why Valens and Medipharm both decided to go with the trade secrets route. (e.g. Kentucky Fried Chicken)  



Canopy assigned patent

What is claimed is: 

 

1. A process for producing an extract containing Tetrahydrocannabinol (THC) and/or cannabidiol (CBD), and optionally the carboxylic acids thereof, from a cannabis plant material or a primary extract thereof, said process comprising: (1) subjecting the cannabis plant material or primary extract thereof to CO2 in liquefied form under subcritical pressure and temperature conditions to extract cannabinoid components; and (2) reducing the pressure and/or temperature to separate tetrahydrocannabinol and/or cannabidiol, and optionally the carboxylic acids thereof, from the CO2. 

 

2. The process according to claim 1, further comprising subjecting the CO2 extracted from step (2) to increased pressure and temperature and recycling said CO2 to step (1). 

 

3. The process according to claim 1, wherein in step (1) the CO2 in liquefied form is at a pressure of 70 bar or less. 

 

4. The process according to claim 3, wherein in step (1) the CO2 in liquefied form is at a temperature of between about 20C to about 30C. 

 

5. The process according to claim 1, wherein in step (1) the CO2 in liquefied form is at a pressure of about 60 bar. 

 

6. The process according to claim 1, wherein in step (2) the CO2 in liquefied form is at a pressure of about 55 bar or less. 

 

7. The process according to claim 3, wherein in step (2) the CO2 in liquefied form is at a pressure of about 55 bar or less and a temperature of about 20C or less. 

 

8. The process according to claim 1, which further comprises separating monoterpenes and sequiterpenes from the tetrahydrocannabinol and cannabidiol using a separator. 

 

9. The process according to claim 1, wherein the cannabis plant material contains 0.5% or less of DELTA9-THC based on the dry plant mass.

 

GW assigned patent
A method for extracting cannabinoids from plant material comprising a decarboxylation step, extraction with liquid carbon dioxide (CO 2 ) and a step of reducing the content of non-interest materials into the extract, characterized in that the extraction with liquid CO 2 at subcritical conditions at a temperature in the range of 5 to 15 ° C and a pressure in the range of 50 to 70 bar, and wherein the step of reducing the content of non-interest materials in the extract is a precipitation with a C1-C5 alcohol, wherein the material to be treated is heated to a temperature above room temperature prior to the addition of the C1-C5 alcohol.

 




Gotime2 wrote: I'm sure you are right, jazz is not concerned with CO2 extraction patents. The value in GW Pharma is in their epilepsy drug patents.
If canopy wins and GW can no longer extract using their CO2 equipment they could just hire a third-party extractor like next leaf 


<< Previous
Bullboard Posts
Next >>